AARTIDRUGS vs ASTRAZEN: Stock Comparison

AARTI DRUGS vs ASTRAZENECA PHARMA IND LTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

ASTRAZENECA PHARMA IND LT is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E, while ASTRAZENECA PHARMA IND LT shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 5; ASTRAZEN leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSASTRAZEN

Valuation lens

What price are you paying?

Market CapContext only
₹3,973 Cr
₹17,288 Cr
P/E RatioAARTIDRUGS has the lower reading
20x
101.61x
P/B RatioAARTIDRUGS has the lower reading
2.47x
19.75x
EPSASTRAZEN has the higher reading
₹5.57
₹15.17
Book ValueContext only
₹169.74
₹349.12
Dividend YieldASTRAZEN has the higher reading
0.46%
0.52%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ASTRAZEN is the larger company
₹17,288 Cr vs ₹3,973 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
20x vs 101.61x
P/B Ratio
AARTIDRUGS has a lower P/B
2.47x vs 19.75x
EPS
ASTRAZEN has higher earnings per share
₹15.17 vs ₹5.57
Dividend Yield
ASTRAZEN has a higher dividend yield
0.52% vs 0.46%
Revenue Growth (TTM YoY)
ASTRAZEN has faster revenue growth
20.4% vs 6.4%
EPS Growth (TTM YoY)
AARTIDRUGS has faster EPS growth
-12% vs -23%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
-10.72% vs -69.99%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSASTRAZEN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSASTRAZEN
Live Price₹431.65₹6,944
Day Change1.36%0.05%
Volume2.5 L6,489
52-Week High₹534.55₹9,849.5
52-Week Low₹318.95₹6,835
Distance from 52W High-19.25%-29.5%

Valuation

MetricAARTIDRUGSASTRAZEN
Market Cap₹3,973 Cr₹17,288 Cr
P/E Ratio20x101.61x
P/B Ratio2.47x19.75x
EPS₹5.57₹15.17
Book Value₹169.74₹349.12
Dividend Yield0.46%0.52%

Growth

MetricAARTIDRUGSASTRAZEN
Revenue Growth (TTM YoY)6.4%20.4%
EPS Growth (TTM YoY)-12%-23%
Qtr Sales Growth-10.72%-69.99%
Qtr Profit Growth1.44%-79.77%

Profitability & Leverage

MetricAARTIDRUGSASTRAZEN
ROE12.05%21.49%
ROCE10.64%44.9%
Net Margin7.6%8.24%
Operating Margin9.19%11.28%
Debt to Equity0.3x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIDRUGSASTRAZEN
Promoter Holding54.43% 0.6 pp0%
FII Holding1.52% 0.06 pp2.68% 0.1 pp
DII Holding10.29% 0.07 pp6.08% 0.28 pp
Public Holding33.75% 0.57 pp16.24% 0.18 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and ASTRAZENECA PHARMA IND LT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.